SCHEMBL852135

SCHEMBL852135

N#Cc1ccc(Oc2ccc(NS(=O)(=O)c3cccc4cccnc34)c(Oc3ccc(C#N)cc3)n2)cc1

nearest known ligand 0.70

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ST14 Q9Y5Y6 1/20 0.70
GLO1 Q04760 3/20 0.56
SLC40A1 Q9NP59 4/20 0.51
TP53 P04637 1/20 0.48
HTT P42858 1/20 0.48
ALDH1A1 P00352 2/20 0.47
GAA P10253 2/20 0.47
POLB P06746 1/20 0.47
TSHR P16473 1/20 0.47
CKS1B P61024 1/20 0.47
SKP2 Q13309 1/20 0.47
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
ATM Q13315 1/20 0.46
SLC16A3 O15427 1/20 0.45
PKLR P30613 1/20 0.44
MMP2 P08253 1/20 0.44
FABP1 P07148 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL852138 0.83 ST14 (1.00) ST14TP53HTTALDH1A1GAA
SCHEMBL851125 0.83 ST14 (0.83) ST14TP53HTTALDH1A1GAA
SCHEMBL851853 0.78 ST14 (0.74) ST14SLC40A1TP53HTTALDH1A1
SCHEMBL850942 0.78 ST14 (0.68) ST14GLO1POLBCKS1BSKP2
SCHEMBL851158 0.76 ST14 (0.67) ST14GLO1MEN1KMT2A
SCHEMBL850945 0.74 ST14 (0.68) ST14GLO1SLC40A1CKS1BSKP2
SCHEMBL13486175 0.73 GLO1 (1.00) GLO1SLC40A1HTTALDH1A1CKS1B
SCHEMBL30925511 0.73 GLO1 (1.00) GLO1SLC40A1HTTALDH1A1CKS1B
SCHEMBL1507919 0.70 SLC40A1 (0.76) GLO1SLC40A1ALDH1A1GAAPOLB
SCHEMBL30854809 0.70 SLC40A1 (0.76) GLO1SLC40A1ALDH1A1GAAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140200225-A1 PROTEASE INHIBITORS ORION CORPORATION (FI) 2014-07-17 US disclosed
US-8722930-B2 Protease inhibitors ORION CORPORATION (FI) 2014-05-13 US disclosed
US-20120136002-A1 PROTEASE INHIBITORS AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2012-05-31 US disclosed
EP-2432556-A1 PROTEASE INHIBITORS Orion Corporation (FI) 2012-03-28 EP disclosed
WO-2010133748-A1 PROTEASE INHIBITORS ORION CORPORATION (FI) 2010-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140200225-A1 PROTEASE INHIBITORS SERPINB1, TMPRSS15, PRSS1 ST14 216/4885GLO1 2062/4885SLC40A1 3285/4885
US-20120136002-A1 PROTEASE INHIBITORS SERPINB1, TMPRSS15, PRSS1 ST14 216/4885GLO1 2062/4885SLC40A1 3285/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.